AbCellera Biologics Inc

ABCL

Equity

ISIN null / Valor 58489933

NASDAQ (2026-05-04)

USD 4.59+3.61%

AbCellera Biologics Inc
UMushroom community rating:

4.00 1 votes No rating yet

NegativeNeutralPositive

About company

AbCellera Biologics Inc. is a biotechnology firm specializing in the discovery and development of antibody-based drugs. The company leverages its proprietary technologies to identify novel antibody candidates for a range of diseases, with a particular focus on creating potential first-in-class and best-in-class antibody medicines. AbCellera's approach includes the development of T-cell engagers for cancer treatment and antibodies targeting transmembrane proteins for various conditions such as metabolic and endocrine disorders, pain, autoimmunity, and more. Through both its internal pipeline and partnerships with other companies that offer novel science or innovative technology, AbCellera aims to accelerate the delivery of innovative medicines to patients. The company's efforts in developing a diverse array of fully human CD3-binding antibodies for T-cell engagers highlight its commitment to advancing the field of immunotherapy and addressing the limitations of current clinical developments.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

90.5%1Y

-30.6%3Y

-83.6%5Y

Performance

77.1%1Y

65.5%3Y

67.5%5Y

Volatility